China Nuclear Imaging Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The China Nuclear Imaging Market is Segmented by Product (Equipment, Radioisotope, and PET Radioisotopes) and Application (SPECT Application and PET Application). The report offers values in USD million for all the above-mentioned segments.

China Nuclear Imaging Market Size

View Global Report

Compare market size and growth of China Nuclear Imaging Market with other markets in Healthcare Industry

China Nuclear Imaging Market Analysis

The China Nuclear Imaging Market size is estimated at USD 362.57 million in 2025, and is expected to reach USD 443.46 million by 2030, at a CAGR of 4.11% during the forecast period (2025-2030).

During the early phase of the pandemic, the Chinese government froze nationwide public transportation, which, in turn, halted all imaging and therapy in the Nuclear Medicine departments, and radioimmunoassay procedures were postponed till the situation returned to normal. The supply of Radiopharmaceuticals is showing a recovery phase by managing the adverse impact of COVID-19 in China. For instance, in April 2022, the China Isotope & Radiation Corporation (CIRC), a company that is involved in radioactive sources and irradiation, and Nuclear Medicine, stated that, while resolving the issues brought on by the COVID-19 pandemic, the company transitioned into the 14th five-year plan. The yearly report showed steady growth and strong financial achievement for 2021. Thus, the companies are recovering from the adverse impact of COVID-19 and are expected to do the same over the forecast period.

The major factors driving the growth of the Chinese Nuclear Imaging market include the rising burden of chronic diseases, increasing technological advancements, and growth in Nuclear Medicine and imaging applications. One of the major chronic diseases in China includes dementia, which can be diagnosed using Nuclear Medicine Imaging techniques. Hence, with the increasing burden of dementia in the region, it is expected to have significant growth in the market. For instance, as per the study published by the Journal of Psychogeriatrics in November 2022, the prevalence of dementia was high among older adults residing in Xiamen, China. Thus, the demand for Nuclear Imaging increases with the high prevalence of dementia and is expected to boost the growth of the market over the forecast period.

Furthermore, with new centers for radioisotope research in the region, it is expected to have new applications and boost the market's growth. For instance, in February 2022, INVAP, an Argentine company, stated that the Nuclear Medicine research and radioisotope production facility would be constructed in China due to the interest in Argentine technology for Nuclear Medicine. Hence, China formulated a national plan to produce Molybdenum-99 and other radioisotopes for medical use. Thus, with the new Nuclear Medicine research facility in China, the demand for Radiopharmaceuticals is expected to increase, which would help the market to grow over the forecast period.

However, the shorter half-life of Radiopharmaceuticals and the high cost of the techniques are anticipated to hamper the growth of the market over the forecast period.

China Nuclear Imaging Industry Overview

The market comprises major market players, and these players are focusing on R&D to strengthen their position in the market. The market has been noticing technological developments on a large scale in Nuclear Imaging Systems and Nuclear Medicine Equipment over the past couple of years. Some of the market players are Bayer AG, Bracco Imaging SpA, Canon Inc., Cardinal Health Inc., China Isotope & Radiation Corporation (CIRC), Curium Pharma, General Electric Company (GE HealthCare), Global Medical Solutions Ltd, Koninklijke Philips NV, Siemens Healthcare GmbH, and Yantai Dongcheng Pharmaceutical Group Co. Ltd.

China Nuclear Imaging Market Leaders

  1. Bracco Imaging SpA

  2. Canon Inc.

  3. Koninklijke Philips NV

  4. Cardinal Health Inc.

  5. General Electric Company (GE HealthCare)

  6. *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF

China Nuclear Imaging Market News

  • August 2022: IBA (Ion Beam Applications S.A), a provider of radiopharmaceutical production solutions, signed a collaboration agreement with Chengdu New Radiomedicine Technology Co. Ltd (CNRT) to install a Cyclone IKON in Chengdu, Sichuan Province, China. The Cyclone IKON is IBA's new high-energy and high-capacity cyclotron which offers the largest energy spectrum for PET and SPECT isotopes from 13 MeV to 30 MeV. CNRT is a Chinese manufacturer and provider of medical isotopes used for oncology diagnosis and therapy.
  • January 2022: ImaginAb and DongCheng Pharmaceutical Group formed a partnership to bring ImaginAb's CD8 ImmunoPET agent, zirconium Zr 89 crefmirlimab berdoxam product, into the Chinese market.

China Nuclear Imaging Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of Chronic Diseases
    • 4.2.2 Increasing Technological Advancements with Growth in Applications of Nuclear Imaging
  • 4.3 Market Restraints
    • 4.3.1 High Cost of the Techniques
    • 4.3.2 Short Half-life of Radiopharmaceuticals
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product
    • 5.1.1 Equipment
    • 5.1.2 Radioisotope
    • 5.1.2.1 SPECT Radioisotopes
    • 5.1.2.1.1 Technetium-99m (TC-99m)
    • 5.1.2.1.2 Thallium-201 (TI-201)
    • 5.1.2.1.3 Gallium (Ga-67)
    • 5.1.2.1.4 Iodine (I-123)
    • 5.1.2.1.5 Other SPECT Radioisotopes
    • 5.1.2.2 PET Radioisotopes
    • 5.1.2.2.1 Fluorine-18 (F-18)
    • 5.1.2.2.2 Rubidium-82 (RB-82)
    • 5.1.2.2.3 Other PET Radioisotopes
  • 5.2 By Application
    • 5.2.1 SPECT Applications
    • 5.2.1.1 Neurology
    • 5.2.1.2 Cardiology
    • 5.2.1.3 Thyroid
    • 5.2.1.4 Other SPECT Applications
    • 5.2.2 PET Applications
    • 5.2.2.1 Oncology
    • 5.2.2.2 Cardiology
    • 5.2.2.3 Neurology
    • 5.2.2.4 Other PET Applications

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bayer AG
    • 6.1.2 Bracco Imaging SpA
    • 6.1.3 Canon Inc.
    • 6.1.4 Cardinal Health Inc.
    • 6.1.5 China Isotope & Radiation Corporation (CIRC)
    • 6.1.6 Curium Pharma
    • 6.1.7 General Electric Company (GE HealthCare)
    • 6.1.8 Global Medical Solutions Ltd
    • 6.1.9 Koninklijke Philips NV
    • 6.1.10 Siemens Healthcare GmbH
    • 6.1.11 Yantai Dongcheng Pharmaceutical Group Co. Ltd
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

China Nuclear Imaging Industry Segmentation

Nuclear medicine imaging procedures are non-invasive and, with the exception of intravenous injections, are usually painless medical tests that help physicians diagnose and evaluate medical conditions. Nuclear imaging scans use radioactive materials called radiopharmaceuticals or radiotracers. The Chinese nuclear imaging market is segmented by product (equipment, radioisotope, and PET radioisotopes) and application (SPECT application and PET application). The report offers values in USD million for all the above-mentioned segments.

By Product Equipment
Radioisotope SPECT Radioisotopes Technetium-99m (TC-99m)
Thallium-201 (TI-201)
Gallium (Ga-67)
Iodine (I-123)
Other SPECT Radioisotopes
PET Radioisotopes Fluorine-18 (F-18)
Rubidium-82 (RB-82)
Other PET Radioisotopes
By Application SPECT Applications Neurology
Cardiology
Thyroid
Other SPECT Applications
PET Applications Oncology
Cardiology
Neurology
Other PET Applications
Need A Different Region or Segment?
Customize Now

China Nuclear Imaging Market Research FAQs

How big is the China Nuclear Imaging Market?

The China Nuclear Imaging Market size is expected to reach USD 362.57 million in 2025 and grow at a CAGR of 4.11% to reach USD 443.46 million by 2030.

What is the current China Nuclear Imaging Market size?

In 2025, the China Nuclear Imaging Market size is expected to reach USD 362.57 million.

Who are the key players in China Nuclear Imaging Market?

Bracco Imaging SpA, Canon Inc., Koninklijke Philips NV, Cardinal Health Inc. and General Electric Company (GE HealthCare) are the major companies operating in the China Nuclear Imaging Market.

What years does this China Nuclear Imaging Market cover, and what was the market size in 2024?

In 2024, the China Nuclear Imaging Market size was estimated at USD 347.67 million. The report covers the China Nuclear Imaging Market historical market size for years: 2021, 2022, 2023 and 2024. The report also forecasts the China Nuclear Imaging Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

China Nuclear Imaging Industry Report

Statistics for the 2025 China Nuclear Imaging market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. China Nuclear Imaging analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

China Nuclear Imaging Market Report Snapshots

China Nuclear Imaging Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)